Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2017

01-06-2017 | Special Article

Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology

Authors: P. Pérez-Segura, J. E. Palacio, L. Vázquez, S. Monereo, R. de las Peñas, P. Martínez de Icaya, C. Grávalos, A. Lecube, A. Blasco, J. M. García-Almeida, I. Barneto, A. Goday

Published in: Clinical and Translational Oncology | Issue 6/2017

Login to get access

Abstract

The relationship between obesity and cancer is clear and is present at all times during course of the disease. The importance of obesity in increasing the risk of developing cancer is well known, and some of the most prevalent tumours (breast, colorectal, and prostate) are directly related to this risk increase. However, there is less information available on the role that obesity plays when the patient has already been diagnosed with cancer. Certain data demonstrate that in some types of cancer, obese patients tolerate the treatments more poorly. Obesity is also known to have an impact on the prognosis, favouring lower survival rates or the appearance of secondary tumours. In this consensus statement, we will analyse the scientific evidence on the role that obesity plays in patients already diagnosed with cancer, and the available data on how obesity control can improve the quality of daily life for the cancer patient.
Appendix
Available only for authorised users
Literature
1.
Gutierrez-Fisac JL, Guallar-Castillon P, Leon-Munoz LM, Graciani A, Banegas JR, Rodriguez-Artalejo F. Prevalence of general and abdominal obesity in the adult population of Spain, 2008–2010: the ENRICA study. Obes Rev. 2012;13:388–92.CrossRefPubMed
2.
Goday A, Barneto I, Garcia-Almeida JM, Blasco A, Lecube A, Gravalos C, et al. Obesity as a risk factor in cancer: a national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015;17:763–71.CrossRefPubMed
3.
Alcaraz Cebrián F, Alcázar Lázaro V, Arriera Blanco F, Azcárate Villalón A, Balsa Barro JA, Barrio Carreras D, et al. Obesidad. Manual teórico-práctico. Madrid: Díaz de Santos; 2011.
4.
Salas-Salvadó J, García Lorda P, Bulló Bonet M, Márquez Sandoval YF. Sobrepeso y obesidad. Sociedad Española para el Estudio de la Obesidad (SEEDO); 2012.
5.
Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, et al. American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol. 2014;32:3568–74.CrossRefPubMedPubMedCentral
6.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.CrossRefPubMed
7.
Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25:1901–14.CrossRefPubMedPubMedCentral
8.
Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O’Connell MJ, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98:1647–54.CrossRefPubMed
9.
10.
Wee CC, McCarthy EP, Davis RB, Phillips RS. Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med. 2000;132:697–704.CrossRefPubMed
11.
Mitchell RS, Padwal RS, Chuck AW, Klarenbach SW. Cancer screening among the overweight and obese in Canada. Am J Prev Med. 2008;35:127–32.CrossRefPubMed
12.
Deneuve S, Tan HK, Eghiaian A, Temam S. Management and outcome of head and neck squamous cell carcinomas in obese patients. Oral Oncol. 2011;47:631–5.CrossRefPubMed
13.
Hauspy J, Jimenez W, Rosen B, Gotlieb WH, Fung-Kee-Fung M, Plante M. Laparoscopic surgery for endometrial cancer: a review. J Obstet Gynaecol Can. 2010;32:570–9.CrossRefPubMed
14.
Chern H, Chou J, Donkor C, Shia J, Guillem JG, Nash GM, et al. Effects of obesity in rectal cancer surgery. J Am Coll Surg. 2010;211:55–60.CrossRefPubMed
15.
De Martino RR, Goodney PP, Spangler EL, Wallaert JB, Corriere MA, Rzucidlo EM, et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg. 2012;55:1035–1040.CrossRefPubMedPubMedCentral
16.
Haakinson DJ, Leeds SG, Dueck AC, Gray RJ, Wasif N, Stucky CC, et al. The impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol. 2012;19:3012–8.CrossRefPubMed
17.
Stewart SB, Freedland SJ. Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol Oncol. 2011;29:476–86.CrossRefPubMed
18.
Kayani B, Okabayashi K, Ashrafian H, Harling L, Rao C, Darzi A, et al. Does obesity affect outcomes in patients undergoing esophagectomy for cancer? A meta-analysis. World J Surg. 2012;36:1785–95.CrossRefPubMed
19.
Lin LL, Hertan L, Rengan R, Teo BK. Effect of body mass index on magnitude of setup errors in patients treated with adjuvant radiotherapy for endometrial cancer with daily image guidance. Int J Radiat Oncol Biol Phys. 2012;83:670–5.CrossRefPubMed
20.
Wong JR, Gao Z, Merrick S, Wilson P, Uematsu M, Woo K, et al. Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images. Int J Radiat Oncol Biol Phys. 2009;75:49–55.CrossRefPubMed
21.
Martra F, Kunos C, Gibbons H, Zola P, Galletto L, DeBernardo R, et al. Adjuvant treatment and survival in obese women with endometrial cancer: an international collaborative study. Am J Obstet Gynecol. 2008;198:89 e1–8.CrossRefPubMed
22.
Keshtgar MR, Vaidya JS, Tobias JS, Wenz F, Joseph D, Stacey C, et al. Targeted intraoperative radiotherapy for breast cancer in patients in whom external beam radiation is not possible. Int J Radiat Oncol Biol Phys. 2011;80:31–8.CrossRefPubMed
23.
Davies BJ, Smaldone MC, Sadetsky N, Dall’era M, Carroll PR. The impact of obesity on overall and cancer specific survival in men with prostate cancer. J Urol. 2009;182:112–7 (discussion 7).
24.
Folkerd EJ, Dixon JM, Renshaw L, A’Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30:2977–80.CrossRefPubMed
25.
Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28:3411–5.CrossRefPubMed
26.
Pfeiler G, Stoger H, Dubsky P, Mlineritsch B, Singer C, Balic M, et al. Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. Br J Cancer. 2013;108:1408–14.CrossRefPubMedPubMedCentral
27.
Pfeiler G, Konigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29:2653–9.CrossRefPubMed
28.
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9:1039–47.CrossRefPubMedPubMedCentral
29.
30.
Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, et al. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2012;110:492–8.CrossRefPubMed
31.
Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 1958;18:853–6.PubMed
32.
Bandera EV, Lee VS, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Impact of chemotherapy dosing on ovarian cancer survival according to body mass index. JAMA Oncol. 2015;1:737–45.CrossRefPubMedPubMedCentral
33.
Shem-Tov N, Labopin M, Moukhtari L, Ciceri F, Esteve J, Giebel S, et al. Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncologist. 2015;20:50–5.CrossRefPubMed
34.
Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30:1553–61.CrossRefPubMed
35.
36.
Mullan F. Seasons of survival: reflections of a physician with cancer. N Engl J Med. 1985;313:270–3.CrossRefPubMed
37.
Blanchard CM, Courneya KS, Stein K, American Cancer Society’s SCS, II. Cancer survivors’ adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society’s SCS-II. J Clin Oncol. 2008;26:2198–204.CrossRefPubMed
38.
Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309:2371–81.CrossRefPubMedPubMedCentral
39.
Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2328–38.CrossRefPubMedPubMedCentral
40.
41.
Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Sablin MP, et al. Beyond axillary lymph node metastasis, BMI and menopausal status are prognostic determinants for triple-negative breast cancer treated by neoadjuvant chemotherapy. PLoS One. 2015;10:e0144359.CrossRefPubMedPubMedCentral
42.
Nechuta S, Chen WY, Cai H, Poole EM, Kwan ML, Flatt SW, et al. A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer. 2016;138:2088–97.CrossRefPubMed
43.
Daniel CR, Shu X, Ye Y, Gu J, Raju GS, Kopetz S, et al. Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre. Br J Cancer. 2016;114:103–9.CrossRefPubMed
44.
Koutoukidis DA, Knobf MT, Lanceley A. Obesity, diet, physical activity, and health-related quality of life in endometrial cancer survivors. Nutr Rev. 2015;73:399–408.CrossRefPubMedPubMedCentral
45.
Smits A, Smits E, Lopes A, Das N, Hughes G, Talaat A, et al. Body mass index, physical activity and quality of life of ovarian cancer survivors: time to get moving? Gynecol Oncol. 2015;139:148–54.CrossRefPubMed
46.
Ligibel JA, Alfano CM, Hershman D, Ballard RM, Bruinooge SS, Courneya KS, et al. Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. J Clin Oncol. 2015;33:3961–7.CrossRefPubMed
47.
Gargallo Fernandez Manuel M, Breton Lesmes I, Basulto Marset J, Quiles Izquierdo J, Formiguera Sala X, Salas-Salvado J, et al. Evidence-based nutritional recommendations for the prevention and treatment of overweight and obesity in adults (FESNAD-SEEDO consensus document). The role of diet in obesity treatment (III/III). Nutr Hosp. 2012;27:833–64.PubMed
48.
Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62:30–67.CrossRefPubMed
49.
50.
51.
Arends J, Bodoky G, Bozzetti F, Fearon K, Muscaritoli M, Selga G, et al. ESPEN Guidelines on Enteral Nutrition: non-surgical oncology. Clin Nutr. 2006;25:245–59.CrossRefPubMed
52.
53.
Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34:611–35.CrossRefPubMed
54.
Campbell KL, Foster-Schubert KE, Alfano CM, Wang CC, Wang CY, Duggan CR, et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J Clin Oncol. 2012;30:2314–26.CrossRefPubMedPubMedCentral
55.
56.
Demark-Wahnefried W, Rogers LQ, Alfano CM, Thomson CA, Courneya KS, Meyerhardt JA, et al. Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin. 2015;65:167–89.CrossRefPubMed
57.
Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62:243–74.CrossRefPubMed
58.
Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293:2479–86.CrossRefPubMed
59.
Merchant SJ, Chen SL. Prevention and management of lymphedema after breast cancer treatment. Breast J. 2015;21:276–84.CrossRefPubMed
60.
Courneya KS, Booth CM, Gill S, O’Brien P, Vardy J, Friedenreich CM, et al. The colon health and life-long exercise change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group. Curr Oncol. 2008;15:279–85.CrossRefPubMed
61.
Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29:726–32.CrossRefPubMedPubMedCentral
62.
Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42:1409–26.CrossRefPubMed
63.
Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–62.CrossRefPubMed
64.
Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J, et al. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes Metab. 2014;16:850–60.CrossRefPubMed
65.
Duntas LH. Clinical comments related to medullary thyroid cancer diagnosis and management. Thyroid Res. 2013;6(Suppl 1):S6.PubMedPubMedCentral
66.
Gagne DJ, Papasavas PK, Maalouf M, Urbandt JE, Caushaj PF. Obesity surgery and malignancy: our experience after 1500 cases. Surg Obes Relat Dis. 2009;5:160–4.CrossRefPubMed
67.
Gianos M, Abdemur A, Szomstein S, Rosenthal R. Laparoscopic sleeve gastrectomy as a step approach for morbidly obese patients with early stage malignancies requiring rapid weight loss for a final curative procedure. Obes Surg. 2013;23:1370–4.CrossRefPubMed
68.
Kim JW, Kim KY, Lee SC, Yang DH, Kim BC. The effect of long Roux-en-Y gastrojejunostomy in gastric cancer patients with type 2 diabetes and body mass index <35 kg/m2: preliminary results. Ann Surg Treat Res. 2015;88:215–21.CrossRefPubMedPubMedCentral
69.
Bretault M, Boillot A, Muzard L, Poitou C, Oppert JM, Barsamian C, et al. Clinical review: bariatric surgery following treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis. J Clin Endocrinol Metab. 2013;98:2239–46.CrossRefPubMed
70.
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 2014;15:23–34.CrossRefPubMed
71.
72.
Bultz BD, Cummings GG, Grassi L, Travado L, Hoekstra-Weebers J, Watson M. 2013 President’s Plenary International Psycho-oncology Society: embracing the IPOS standards as a means of enhancing comprehensive cancer care. Psychooncology. 2014;23:1073–8.CrossRefPubMed
73.
Lepore SJ, Coyne JC. Psychological interventions for distress in cancer patients: a review of reviews. Ann Behav Med. 2006;32:85–92.CrossRefPubMed
74.
Villoria E, Fernandez C, Padierna C, Gonzalez S. La intervención psicológica en pacientes oncológicos: una revisión de la literatura (2000-2014). Psicooncología. 2015;12:207–36.
75.
Metadata
Title
Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
Authors
P. Pérez-Segura
J. E. Palacio
L. Vázquez
S. Monereo
R. de las Peñas
P. Martínez de Icaya
C. Grávalos
A. Lecube
A. Blasco
J. M. García-Almeida
I. Barneto
A. Goday
Publication date
01-06-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1601-2

Other articles of this Issue 6/2017

Clinical and Translational Oncology 6/2017 Go to the issue

Research Article

Impact of clinicopathological parameters on survival after multiorgan resection among patients with T4 gastric carcinoma: a systematic review and meta-analysis

Research Article

Neutrophil to lymphocyte ratio associated with prognosis of lung cancer

Research Article

Role of axillary ultrasound, magnetic resonance imaging, and ultrasound-guided fine-needle aspiration biopsy in the preoperative triage of breast cancer patients

Review Article

Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it

Special Article

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

Research Article

Nasopharyngeal carcinoma: 30-year experience of a single institution in a non-endemic area
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits